Evaxion A/S (EVAX) Reports 3-Year Durability for EVX-01 in Phase 2 Melanoma Trial
Evaxion A/S (EVAX) reported 3-year durability data for its EVX-01 melanoma trial, showing no tumor progression and maintained responses. The 2-year data had a 75% ORR, with 25% complete responses. Results will be presented at ESMO 2026 Congress and a webinar. According to the company, all patients at 3-year follow-up maintained prior responses.
How this was made
The 30-second read
Why it matters
The three‑year follow‑up confirms sustained responses, reducing perceived risk and potentially attracting partnership or funding.
Market read
First disclosure of three‑year durability data; likely to move EVAX stock and influence sector sentiment.
What to watch
Regulatory pathway, manufacturing scale‑up, and competition from other melanoma therapies.
Background
Evaxion A/S is a Danish biotech developing personalized cancer vaccines. The EVX-01 candidate has previously reported a 75% objective response rate at two years.
Ticker impact
Evaxion A/S disclosed three-year durability data for its EVX-01 melanoma vaccine, showing no tumor progression and sustained responses.
upward pressure as investors price in durable efficacy and de‑risk development.
Phase‑2 durability data is a material clinical milestone; biotech stocks typically rally on such news.
Market effects
Strengthens the oncology vaccine sub‑sector and may boost peer biotech sentiment.
European biotech investors could see increased interest.
Limited to biotech investors; no broad market effect.
Counterpoint
Durability data alone may not translate to commercial success without larger controlled trials.
Key entities
- companyEvaxion A/S
Developer of the EVX-01 melanoma vaccine.